Panagora Asset Management Inc. Has $286,000 Stock Position in NewLink Genetics Corp (NASDAQ:NLNK)

Panagora Asset Management Inc. lowered its position in shares of NewLink Genetics Corp (NASDAQ:NLNK) by 71.2% in the second quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 193,260 shares of the biotechnology company’s stock after selling 477,815 shares during the quarter. Panagora Asset Management Inc. owned approximately 0.52% of NewLink Genetics worth $286,000 at the end of the most recent quarter.

Separately, Requisite Capital Management LLC acquired a new stake in shares of NewLink Genetics during the 2nd quarter worth about $185,000. Institutional investors own 29.32% of the company’s stock.

Shares of NewLink Genetics stock traded up $0.01 during mid-day trading on Friday, reaching $1.94. 507 shares of the stock were exchanged, compared to its average volume of 210,522. The company has a market cap of $72.75 million, a price-to-earnings ratio of -1.34 and a beta of 1.21. The company has a current ratio of 12.77, a quick ratio of 12.77 and a debt-to-equity ratio of 0.08. The firm has a 50-day simple moving average of $1.62 and a 200 day simple moving average of $1.67. NewLink Genetics Corp has a fifty-two week low of $1.28 and a fifty-two week high of $2.68.



NewLink Genetics (NASDAQ:NLNK) last posted its quarterly earnings data on Tuesday, July 30th. The biotechnology company reported ($0.27) earnings per share for the quarter, beating the consensus estimate of ($0.29) by $0.02. The firm had revenue of $0.15 million during the quarter. NewLink Genetics had a negative net margin of 6,587.56% and a negative return on equity of 34.44%. On average, research analysts predict that NewLink Genetics Corp will post -0.03 EPS for the current fiscal year.

A number of equities research analysts recently issued reports on NLNK shares. Zacks Investment Research upgraded shares of NewLink Genetics from a “hold” rating to a “buy” rating and set a $2.00 target price for the company in a research report on Saturday, August 3rd. ValuEngine upgraded shares of NewLink Genetics from a “sell” rating to a “hold” rating in a research report on Thursday, August 1st.

About NewLink Genetics

NewLink Genetics Corporation, a late clinical-stage immuno-oncology company, focuses on discovering and developing novel immunotherapeutic products for the treatment of patients with cancer. It is developing Indoximod, an indoleamine-2, 3-dioxygenase (IDO) pathway inhibitor that is in clinical development in combination with other cancer therapeutics for patients with diffuse intrinsic pontine glioma, pediatric brain tumors, acute myeloid leukemia, and melanoma.

Recommended Story: Stop Order

Want to see what other hedge funds are holding NLNK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for NewLink Genetics Corp (NASDAQ:NLNK).

Institutional Ownership by Quarter for NewLink Genetics (NASDAQ:NLNK)

Receive News & Ratings for NewLink Genetics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NewLink Genetics and related companies with MarketBeat.com's FREE daily email newsletter.